<DOC>
	<DOC>NCT00192283</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of the liquid formulation of CAIVT against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months, attending day care centers in Europe. In addition, the trial provides the opportunity to investigate the effect of CAIV-T on acute otitis media, on healthcare resource utilization and economic resources.</brief_summary>
	<brief_title>Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A &amp; B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<criteria>who are aged at least 6 months and less than 36 months of age at the time of enrollment, attending day care for at least three days a week, four hours a day; who are in good health as determined by medical history, physical examination and clinical judgement; whose parent(s)/legal guardian(s) have provided written informed consent after the nature of the study has been explained; who, along with their parent(s)/legal guardian(s), will be available for duration of the trial (8 months Â± 1 month); whose parent(s)/legal guardian(s), can be reached by study staff for the postvaccination contacts [telephone, clinic or home visit]. whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period; with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease; with Down's syndrome or other known cytogenetic disorders; with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids; who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study; for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study; have an immunosuppressed or an immunocompromised individual living in the same household; who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational); who, in the two weeks prior to entry into this study, received a dose of any influenza treatment (commercial or investigational); with a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo; with a clinically confirmed respiratory illness with wheezing within two weeks prior to enrollment; who received aspirin (acetylsalicylic acid) or aspirincontaining products in the two weeks prior to enrollment or for which use is anticipated during the study; who were administered any live virus vaccine within one month prior to enrollment or expected to receive another live virus vaccine within one month of vaccination in this study; with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results; If any of these criteria are met following enrolment, the subject will be excluded from subsequent vaccine dosing. Note: A pregnant household member is not considered a contraindication to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>